| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Harvard Bioscience, Inc. (HBIO) has 8 insiders with recent SEC Form 4 filings, including 8 buys and 3 sells. HBIO is classified in the Health Care Equipment & Supplies industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.80M | $16.41M | - | |
| CEO | 180.0K | $1.06M | - | |
| Dir | 58.7K | $344.4K | - | |
| Dir | 48.6K | $285.0K | - | |
| CFO | 47.5K | $278.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 7, 2017 | Green David | Director | Sell | 3,239 | $3.25 | $10,526.75 | -0.3% | |
| Feb 6, 2017 | Green David | Director | Sell | 1,288 | $3.25 | $4,186.00 | -0.1% | |
| Dec 6, 2016 | Lewis Earl R61 | Director | Sell | 23,088 | $2.42 | $55,872.96 | -5.6% | |
| Nov 3, 2016 | Duchemin Jeffrey | Chief Executive Officer | Buy | 15,000 | $2.42 | $36,300.00 | +3.4% | |
| Nov 3, 2016 | Gagnon Robert E.67 | Chief Financial Officer | Buy | 25,000 | $2.34 | $58,450.00 | +5.1% | |
| Dec 10, 2015 | Duchemin Jeffrey | Chief Executive Officer | Buy | 10,000 | $3.37 | $33,700.00 | +6.7% | |
| Dec 3, 2015 | Uveges George | Director | Buy | 3,000 | $3.32 | $9,960.00 | +4.7% | |
| Dec 2, 2015 | Lewis Earl R61 | Director | Buy | 27,221 | $3.28 | $89,284.88 | +7.5% | |
| Nov 12, 2015 | Gagnon Robert E.67 | Chief Financial Officer | Buy | 1,500 | $2.93 | $4,395.00 | +2.3% | |
| Nov 9, 2015 | Gagnon Robert E.67 | Chief Financial Officer | Buy | 3,000 | $3.08 | $9,240.00 | +4.7% |